Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32)

Blood

Volumn 95, Issue 8, 2000, Pages 2691-2698

  Janssen, Johannes W G ^a   Vaandrager, Jan Willem ^b   Heuser, Tanja ^b   Jauch, Anna ^b   Kluin, Philip M ^b   Geelen, Erik ^b   Bergsagel, P Leif ^b   Kuehl, W Michael ^b   Drexler, Hans G ^b   Otsuki, Takemi ^b   Bartram, Claus R ^b   Schuuring, Ed ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GENE PRODUCT; IMMUNOGLOBULIN HEAVY CHAIN; MYEOV PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CHROMOSOME 11Q; CHROMOSOME TRANSLOCATION 11; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYEOV GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYCLIN D1; DNA, NEOPLASM; HUMANS; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034656068     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143.
2. Chen C, Birshtein BK. Virtually identical enhancers containing a segment of homology to murine 3′IgH-E(hs1,2) lie downstream of human Ig C alpha1 and C alpha 2 genes. J Immunol. 1997; 159:1310.
3. Mills FC, Harindranath N, Mitchell M, Max EE. Enhancer complexes located downstream of both human immunoglobulin C alpha genes. J Exp Med. 1997;186:845.
4. Kluin PHM, Vaandrager JW, van Krieken JHJM, Schuuring E. Chromosomal markers in lymphoma diagnosis. Curr Diagn Pathol. 1996; 3:187.
5. Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood. 1990; 75:1848.
6. Müller JR, Janz S, Potter M. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations. Cancer Res. 1995;55:5012.
7. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985; 66:380.
8. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995; 82:41.
9. Laï JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85:2490.
10. Nishida K, Tamura A, Nakazawa N, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1997;90:526.
11. Weh HJ, Gutensohn K, Selbach J, et al. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer. 1993;29A:1269.
12. Taniwaki M, Nishida K, Takashima T, et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood. 1994;84: 2283.
13. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosom Cancer. 1997;18:84.
14. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 1997;90:4062.
15. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960.
16. Avet-Loiseau H, Li J-Y, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998;58:5640.
17. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A. 1996;93:13,931.
18. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260.
19. Iida S, Rao PH, Butler M,et al. Deregulation of MUM/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17:226.
20. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457.
21. Stec I, Wright TJ, van Ommen G-JB, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet. 1998;7:1071.
22. Chesi M, Nardini E, Lim RSC, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92:3025.
23. Janssen JWG, Braunger J, Ballas K, et al. Spectrum of transforming sequences detected by tumorigenicity assay in a large series of human neoplasms. Int J Cancer. 1999;80:857.
24. De Boer CJ, Loyson S, Kluin PM, Kluin-Nelemans HC, Schuuring E, van Krieken JHJM. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 1993;53:4148.
25. De Boer CJ, van Krieken JHJM, Kluin-Nelemans JC, Kluin PM, Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 1995;10:1833.
26. Vaandrager J, Schuuring E, Zwikstra E, et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood. 1996;88:1177.
27. Raynaud SD, Bekri S, Leroux D, et al. Expanded range of 11 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosom Cancer. 1993;8:80.
28. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol. 1989;73:199.
29. Schuuring E, Verhoeven E, Mooi WJ, Micalides RJAM. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene. 1992;7:355.
30. Lichter P, Cremer T. Chromosome analysis by nonisotopic in situ hybridisation. In: Rooney DE, Czepulkowski BH, eds. Human Cylogenetics: A Practical Approach. Vol 1. 2nd ed. Oxford, UK: IRL Press; 1992:157.
31. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A. 1986;83:2934.
32. Coignet LJA, Schuuring E, Kibbelaar RE, et al. Detection of 11q13 rearrangements in hematologic neoplasias by double color fluorescence in situ hybridization. Blood. 1996;87:1512.
33. H gene rearrangements in follicle center-cell lymphoma. Blood. 1998;92:2871.
34. De Boer CJ, Vaandrager JW, van Krieken JHJM, Holmes Z, Kluin PM, Schuuring E. Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization. Oncogene. 1997;15:1599.
35. Brookes S, Lammie GA, Schuuring E, Dickson C, Peters G. Linkage map of a region of human chromosome 11q13 amplified in breast and squamous cell tumors. Genes Chromosom Cancer. 1992;4:290.
36. Bekri S, Adéläide J, Merscher S, et al. Detailed map of a region commonly amplified at 11q13-q14 in human breast carcinoma. Cytogenet Cell Genet. 1997;79:125.
37. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674.
38. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene. 1999;234:187.
39. Nagai K, Oubridge C, Ito N, Avis J, Evans P. The RNP domain: a sequence-specific RNA-binding domain involved in processing and transport of RNA. Trends Biochem Sci. 1995;20:235.
40. Whitley P, Grahn E, Kutay U, Rapoport TA, von Heijne G. A 12-residue-long polyleucine tail is sufficient to anchor synaptobrevin to the endoplasmic reticulum membrane. J Biol Chem. 1996;271: 7583.
41. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene. 1995;159:83.
42. Sinke RJ, Dijkhuizen T, Janssen B, et al. Fine mapping of the human renal oncocytoma-associated translocation (5;11)(q35;q13) breakpoint. Cancer Genet Cytogenet. 1997;96:95.
43. Vaandrager JW, Kluin PM, Schuuring E. The t(11; 14)(q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. Blood. 1997;89:349.
44. Bertrandy S, Burlet P, Clermont O, et al. The RNA-binding properties of SMN: deletion analysis of the zebrafish orthologue defines domains conserved in evolution. Hum Mol Genet. 1999;8:775.
45. Vaandrager JW, Kleiverda JK, Schuuring E, Kluin-Nelemans JC, Raap AK, Kluin PM. Cytogenetics on released DNA fibers. Verh Dtsch Ges Pathol. 1997;81:306.
46. De Boer CJ, Schuuring E, Dreef E, Kluin PhM, van Krieken JHJM. Cyclin D1 protein overexpression as a marker for mantle cell lymphoma. Blood. 1995;86:2715.
47. Ronchetti D, Finelli P, Richelda R, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood. 1999;93:1330.
48. Gabrea A, Bergsagel L, Chesi M, Shou Y, Kuehl WM. Insertion of excised switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119.
49. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998;101:296.
50. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86: 4250.
51. Müller MM, Gerster T, Schaffner W. Enhancer sequences and the regulation of gene transcription. Eur J Biochem. 1988;176:485.
52. Meeus P, Stul MS, Mecucci C, Cassiman JJ, Van Den Berghe H. Molecular breakpoints of t(11; 14)(q13;q32) in multiple myeloma. Cancer Genet Cytogenet. 1995;83:25.